Kenvue Inc. (NYSE:KVUE) Shares Sold by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV lowered its position in Kenvue Inc. (NYSE:KVUE) by 2.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,693 shares of the company’s stock after selling 853 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Kenvue were worth $740,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in KVUE. Stephens Inc. AR raised its stake in shares of Kenvue by 86.1% in the 4th quarter. Stephens Inc. AR now owns 57,694 shares of the company’s stock valued at $1,242,000 after acquiring an additional 26,700 shares during the period. Stifel Financial Corp boosted its position in shares of Kenvue by 60.4% in the fourth quarter. Stifel Financial Corp now owns 745,064 shares of the company’s stock worth $16,041,000 after buying an additional 280,591 shares during the period. Raleigh Capital Management Inc. boosted its position in shares of Kenvue by 93,834.8% in the fourth quarter. Raleigh Capital Management Inc. now owns 43,210 shares of the company’s stock worth $930,000 after buying an additional 43,164 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Kenvue by 2.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 1,598,567 shares of the company’s stock valued at $34,417,000 after buying an additional 40,995 shares in the last quarter. Finally, Cornerstone Wealth Group LLC raised its holdings in shares of Kenvue by 176.2% during the 1st quarter. Cornerstone Wealth Group LLC now owns 350,371 shares of the company’s stock valued at $7,519,000 after buying an additional 223,537 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $23.12 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average price is $21.21 and its two-hundred day moving average price is $20.03. The stock has a market capitalization of $44.27 billion, a P/E ratio of 29.64, a P/E/G ratio of 2.92 and a beta of 1.40. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $23.55.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The firm’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the business earned $0.32 EPS. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 annualized dividend and a yield of 3.55%. Kenvue’s dividend payout ratio (DPR) is currently 105.13%.

Analysts Set New Price Targets

Several analysts have issued reports on KVUE shares. UBS Group increased their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Citigroup dropped their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. Piper Sandler upped their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft raised their target price on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $22.10.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.